AVIR Atea Pharmaceuticals, Inc. Stock Quote

AVIR [NASD]

Index	-	P/E	14.45	EPS (ttm)	0.51	Insider Own	10.52%	Shs Outstand	83.18M	Perf Week	2.80%
Market Cap	591.53M	Forward P/E	-	EPS next Y	-2.56	Insider Trans	0.14%	Shs Float	74.50M	Perf Month	25.68%
Income	48.40M	PEG	-	EPS next Q	-0.52	Inst Own	66.90%	Short Float	3.21%	Perf Quarter	18.01%
Sales	285.40M	P/S	2.07	EPS this Y	-268.60%	Inst Trans	2.78%	Short Ratio	2.95	Perf Half Y	-4.30%
Book/sh	8.17	P/B	0.90	EPS next Y	25.50%	ROA	6.00%	Target Price	7.50	Perf Year	-63.45%
Cash/sh	8.75	P/C	0.84	EPS next 5Y	-	ROE	7.50%	52W Range	5.31 - 46.91	Perf YTD	-17.90%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	17.00%	52W High	-84.35%	Beta	-
Dividend %	-	Quick Ratio	24.90	Sales past 5Y	-	Gross Margin	-	52W Low	38.23%	ATR	0.46
Employees	64	Current Ratio	24.90	Sales Q/Q	295.20%	Oper. Margin	-	RSI (14)	59.69	Volatility	4.99% 7.99%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-246.80%	Profit Margin	17.00%	Rel Volume	0.87	Prev Close	7.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 10 BMO	Payout	0.00%	Avg Volume	811.67K	Price	7.34
Recom	2.60	SMA20	12.90%	SMA50	11.11%	SMA200	-46.84%	Volume	702,723	Change	-2.52%

Jan-06-22

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$14 → $7

Nov-18-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Oct-20-21

Downgrade

JP Morgan

Overweight → Neutral

$61 → $16

Oct-05-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$55

Nov-25-20

Initiated

Evercore ISI

Outperform

Nov-24-20

Initiated

William Blair

Outperform

$60

Nov-24-20

Initiated

Morgan Stanley

Overweight

$49

Nov-24-20

Initiated

JP Morgan

Overweight

$45

May-25-22 06:20AM	Market Participants Recognise Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Earnings Pushing Shares 28% Higher Simply Wall St.
May-11-22 10:28AM	A Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider increased their holdings by 106% last year Simply Wall St.
May-10-22 07:00PM	Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript Motley Fool +9.94%
06:30AM	Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
May-03-22 04:05PM	Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022 GlobeNewswire
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 Investopedia
Mar-30-22 12:48PM	What Kind Of Investors Own Most Of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)? Simply Wall St.
Mar-28-22 07:00AM	Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting GlobeNewswire
Mar-21-22 10:04AM	Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains? Zacks
Feb-28-22 10:00PM	Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript Motley Fool
07:19PM	Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours Winner Motley Fool
06:40PM	Atea Pharma stock jumps as earnings rise, potential COVID-19 therapy advances MarketWatch
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update GlobeNewswire
Feb-22-22 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022 GlobeNewswire
Feb-16-22 02:19PM	8 Biotech Stocks So Cheap That Their Technology Is Effectively Free Barrons.com
01:57PM	8 Biotech Stocks So Cheap That Their Technology Is Effectively Free Barrons.com
Feb-14-22 09:31AM	10 New Stock Picks of Billionaire Rob Citrone Insider Monkey -8.46%
Feb-11-22 07:00AM	Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes Investor's Business Daily
Feb-10-22 07:00AM	Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development GlobeNewswire
Feb-09-22 07:00AM	Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-02-22 05:38PM	Vanguard Capital Wealth Advisors Buys VanEck Gold Miners ETF, ViacomCBS Inc, Uber Technologies ... GuruFocus.com
01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... GuruFocus.com
07:00AM	Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvirs (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications GlobeNewswire
Jan-28-22 05:05AM	With A 4.3% Return On Equity, Is Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) A Quality Stock? Simply Wall St. +5.75%
Jan-07-22 07:00AM	Atea Pharmaceuticals Highlights Strategic Priorities for 2022 GlobeNewswire
Jan-03-22 07:00AM	Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-21 08:27AM	Scoping Out Bargains in Biotech? These 8 Stocks Trade for Less Than Their Cash. Barrons.com
05:00AM	Scoping Out Bargains in Biotech? These 8 Stocks Trade for Less Than Their Cash. Barrons.com
Dec-17-21 07:00AM	Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index GlobeNewswire
Dec-14-21 04:30PM	Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19 GlobeNewswire
Dec-12-21 12:24PM	Hedge Funds Are Piling Into Atea Pharmaceuticals, Inc. (AVIR) Insider Monkey
Dec-10-21 06:38PM	Franklin U.S. Small Capitalization Equity Fund Buys Ovintiv Inc, ShockWave Medical Inc, SM ... GuruFocus.com
Dec-01-21 08:47AM	Implied Volatility Surging for Atea (AVIR) Stock Options Zacks
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital Insider Monkey
Nov-22-21 07:00AM	Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire
Nov-17-21 10:32AM	Atea (AVIR) Plunges on Termination of Collaboration With Roche Zacks -23.50%
08:13AM	Why Atea Pharmaceuticals Stock Is Sinking Today Motley Fool
08:09AM	Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill Benzinga
Nov-16-21 05:25PM	Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill Investor's Business Daily
04:58PM	UPDATE 1-Roche terminates partnership with Atea to develop COVID-19 pill Reuters
04:30PM	Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche GlobeNewswire
Nov-12-21 05:00AM	Atea Pharmaceuticals Inc (AVIR) Q3 2021 Earnings Call Transcript Motley Fool +6.77%
Nov-11-21 04:01PM	Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-04-21 07:53AM	Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021 GlobeNewswire
06:50AM	Is There Any Hope for Atea Pharmaceuticals Stock? Motley Fool
Nov-01-21 03:21PM	11 Best Covid Vaccine and Pill Stocks To Invest In Insider Monkey
Oct-31-21 06:19AM	3 Beaten-Down Biotech Stocks -- Can They Recover? Motley Fool
Oct-30-21 08:39AM	Investors one-year losses grow to 62% as the stock sheds US$90m this past week Simply Wall St.
Oct-29-21 06:05AM	How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market Motley Fool
Oct-26-21 07:00AM	3 Top COVID Stocks -- Are They Tricks or Treats? Motley Fool
06:45AM	Was Atea Pharmaceutical's Flop Predictable? Motley Fool
Oct-25-21 02:39PM	How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More Benzinga
Oct-24-21 10:00AM	Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy? Motley Fool
Oct-22-21 07:42PM	Why Atea Pharmaceuticals Stock Got Crushed This Week Motley Fool
Oct-20-21 09:04PM	J.P. Morgans Bullish Stance on Atea Pharmaceuticals Stock Comes to an End TipRanks
11:10AM	Atea (AVIR) Plunges on Oral COVID Candidate Study Failure Zacks
10:09AM	Atea Reveals Topline Results of Phase 2 MOONSONG Trial; Shares Crash 66% SmarterAnalyst
Oct-19-21 04:05PM	Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test Investor's Business Daily -65.96%
12:55PM	Why Ulta and Atea Rained on the Nasdaq's Parade Tuesday Motley Fool
12:11PM	Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge Benzinga
12:02PM	33 Stocks Moving In Tuesday's Mid-Day Session Benzinga
11:56AM	Why Atea Pharmaceuticals Is Imploding Today Motley Fool
10:08AM	Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance Benzinga
09:51AM	Atea Pharmaceuticals stock rocked after disappointing trial results of SARS-CoV-2 pill MarketWatch
07:00AM	Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting GlobeNewswire
04:28AM	Atea Pharma Stock Plunges After COVID Treatment Trial Disappoints; Merck Jumps TheStreet.com
Oct-17-21 06:04AM	3 Stocks to Consider if the October Stock Market Sell-Off Worsens Motley Fool
Oct-15-21 04:30PM	The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies Investor's Business Daily
Oct-12-21 04:00PM	3 COVID Stocks That Can Turn $1,000 Into $10,000 Motley Fool
Oct-11-21 08:27AM	Merck Submits Covid Pill to FDA for Emergency Approval Barrons.com
Oct-08-21 08:30AM	Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment? Motley Fool
Oct-07-21 07:00AM	Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021 GlobeNewswire
Oct-05-21 10:00AM	Which COVID-19 Pill Stock Is the Best Buy? Motley Fool -5.00%
Oct-04-21 10:00AM	2 Best Biotech Stocks to Buy In October Motley Fool +6.14%
Oct-03-21 04:00PM	3 Stocks That Might Soar With Pills for COVID Motley Fool
Oct-01-21 12:21PM	Why Atea Pharmaceutical Stock Is Ripping Higher Today Motley Fool +19.82%
11:50AM	Vaccine Stocks Crumble As Merck Breaks Out On Its Blockbuster Potential Covid Pill Investor's Business Daily
Sep-29-21 07:00AM	Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference GlobeNewswire
Sep-20-21 01:18PM	Why Atea Pharmaceuticals Is Up 17% Today Motley Fool +10.33%
Sep-18-21 12:11PM	Pills to Battle Covid Are Coming. These Companies Stand to Gain. Barrons.com
Sep-10-21 12:19PM	7 Biotech Stocks to Buy That Have Millionaire-Maker Potential InvestorPlace
Sep-07-21 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference GlobeNewswire
Aug-24-21 07:00AM	Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses GlobeNewswire
Aug-13-21 01:37AM	Read This Before Judging Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) ROE Simply Wall St. -11.06%
12:00AM	Atea Pharmaceuticals Inc (AVIR) Q2 2021 Earnings Call Transcript Motley Fool
Aug-12-21 04:05PM	Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results GlobeNewswire -5.76%
Aug-05-21 07:00AM	Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021 GlobeNewswire
06:39AM	Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar Motley Fool
Aug-04-21 09:39AM	This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money Motley Fool
Jul-12-21 07:00AM	Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference GlobeNewswire
Jun-30-21 11:11AM	Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients Benzinga -12.00%
07:00AM	Ateas AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis GlobeNewswire
Jun-16-21 09:26AM	Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche Benzinga
07:00AM	Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche GlobeNewswire
Jun-15-21 07:00AM	Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs GlobeNewswire
May-26-21 07:00AM	Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-25-21 12:41AM	Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised) Zacks -5.61%
May-20-21 07:00AM	Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors GlobeNewswire +6.42%
May-15-21 03:26AM	Atea Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year Simply Wall St.
May-13-21 04:05PM	Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murphy Polly A.	Director	Dec 20	Buy	8.57	12,000	102,796	23,295	Dec 21 09:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience